2020 has brought COVID to most of the world and disruption across industries. The pharmaceutical industry didn’t escape impact with supply chains disconnected, trials halted, and drug shortages caused by spikes in demand for drugs thought to provide some hope for COVID relief. While COVID has been a supply-side disruption, recovery through the summer has been swift. At the same time, COVID has been a demand side catalyst. Engagement of capacity for vaccine manufacture…at risk…has been astonishing. In this exclusive session, Dave Windley, managing director of Jeffries LLC, will look at growth trends and impacts of COVID on contract manufacturing players.